JPWO2020221821A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020221821A5
JPWO2020221821A5 JP2021564303A JP2021564303A JPWO2020221821A5 JP WO2020221821 A5 JPWO2020221821 A5 JP WO2020221821A5 JP 2021564303 A JP2021564303 A JP 2021564303A JP 2021564303 A JP2021564303 A JP 2021564303A JP WO2020221821 A5 JPWO2020221821 A5 JP WO2020221821A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
gnrh
patient
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021564303A
Other languages
Japanese (ja)
Other versions
JP2022533011A (en
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/061943 external-priority patent/WO2020221821A1/en
Publication of JP2022533011A publication Critical patent/JP2022533011A/en
Publication of JPWO2020221821A5 publication Critical patent/JPWO2020221821A5/ja
Pending legal-status Critical Current

Links

Claims (13)

ゴナドトロピン放出ホルモン（ＧｎＲＨ）を含む、それを必要とする患者における認知障害の処置のための医薬組成物であって、前記ＧｎＲＨが、パルス投与により投与される、前記医薬組成物。 A pharmaceutical composition for the treatment of cognitive impairment in a patient in need thereof comprising gonadotropin-releasing hormone (GnRH), wherein said GnRH is administered by pulsatile administration. ｍｉＲ－２００及び／又はｍｉＲ－１５５を含む、それを必要とする患者における認知障害の処置のための医薬組成物。 A pharmaceutical composition for the treatment of cognitive impairment in a patient in need thereof, comprising miR-200 and/or miR-155. 前記患者が、嗅覚機能障害を有する、請求項１又は請求項２に記載の医薬組成物。 3. The pharmaceutical composition of claim 1 or claim 2, wherein the patient has olfactory dysfunction. 前記認知障害が、ダウン症候群である、請求項１～３のいずれか一項に記載の医薬組成物。 The pharmaceutical composition according to any one of claims 1-3, wherein the cognitive disorder is Down's syndrome. 前記認知障害が、アルツハイマー病である、請求項１～３のいずれか一項に記載医薬組成物。 The pharmaceutical composition according to any one of claims 1-3, wherein the cognitive disorder is Alzheimer's disease. 前記認知障害が、パーキンソン病である、請求項１～３のいずれか一項に記載の医薬組成物。 The pharmaceutical composition according to any one of claims 1-3, wherein the cognitive disorder is Parkinson's disease. 前記認知障害が、加齢に関連付けられる認知低下である、請求項１～３のいずれか一項に記載の医薬組成物。 The pharmaceutical composition according to any one of claims 1 to 3, wherein said cognitive impairment is cognitive decline associated with aging. 前記認知障害が、初期段階中にある、請求項１～６のいずれか一項に記載の医薬組成物。 The pharmaceutical composition of any one of claims 1-6, wherein the cognitive impairment is in the early stages. 前記患者が、男性である、請求項１及び３～８のいずれか一項に記載の医薬組成物。 The pharmaceutical composition according to any one of claims 1 and 3-8, wherein said patient is male. 前記パルス投与が、１２０分毎の２５ng/kgのＧｎＲＨの投与に対応する、請求項９に記載の医薬組成物。 10. The pharmaceutical composition of claim 9, wherein said pulse administration corresponds to administration of 25 ng/kg GnRH every 120 minutes. 前記患者が女性である、請求項１及び３～８のいずれか一項に記載の医薬組成物。 The pharmaceutical composition according to any one of claims 1 and 3-8, wherein said patient is female. 前記パルス投与が、９０分毎の７５ng/kgのＧｎＲＨの投与に対応する、請求項１１に記載の医薬組成物。 12. The pharmaceutical composition of claim 11, wherein said pulse administration corresponds to administration of 75 ng/kg GnRH every 90 minutes. 前記ＧｎＲＨが、ゴナドレリンである、請求項１及び３～１２のいずれか一項に記載の医薬組成物。 The pharmaceutical composition according to any one of claims 1 and 3-12, wherein said GnRH is gonadorelin.
JP2021564303A 2019-04-30 2020-04-29 Pulsed GNRH administration to treat cognitive impairment Pending JP2022533011A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19305550.6 2019-04-30
EP19305550 2019-04-30
PCT/EP2020/061943 WO2020221821A1 (en) 2019-04-30 2020-04-29 Pulsative gnrh administration for treating cognitive disorders

Publications (2)

Publication Number Publication Date
JP2022533011A JP2022533011A (en) 2022-07-21
JPWO2020221821A5 true JPWO2020221821A5 (en) 2023-05-11

Family

ID=66625872

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021564303A Pending JP2022533011A (en) 2019-04-30 2020-04-29 Pulsed GNRH administration to treat cognitive impairment

Country Status (4)

Country Link
US (1) US20220202895A1 (en)
EP (1) EP3962494A1 (en)
JP (1) JP2022533011A (en)
WO (1) WO2020221821A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4267168A1 (en) 2020-12-22 2023-11-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Pulsative gnrh administration for treating food intake related disorders
WO2024047115A1 (en) 2022-09-02 2024-03-07 Leibniz-Institut Für Immuntherapie (Lit) THERAPEUTIC USE OF THE miR155 SNP rs377265631

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0158683B1 (en) 1984-04-14 1988-10-05 Ferring Biotechnik GmbH Device for the intermittent delivery of medicaments
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
US5013293A (en) 1987-05-28 1991-05-07 Drug Delivery Systems Inc. Pulsating transdermal drug delivery system
US20080171736A1 (en) * 2004-12-23 2008-07-17 Gregory Christopher W Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists
EP1928543A2 (en) 2005-09-30 2008-06-11 Vyteris, Inc. Pulsatile delivery of gonadotropin-releasing hormone from a pre-loaded integrated electrotransport patch
WO2014179139A2 (en) * 2013-04-30 2014-11-06 Albert Einstein College Of Medicine Of Yeshiva University TREATMENT OF AGING EFFECTS BY GONADOTROPIN-RELEASING HORMONE, NEUROGENESIS OR BRAIN IKK-β/NF-κΒ INHIBITION
WO2017182580A1 (en) 2016-04-20 2017-10-26 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for the diagnosis and the treatment of reproduction-related disorders and methods for contraception
CN108837143B (en) * 2018-09-29 2022-03-01 南华大学 Application of triptorelin

Similar Documents

Publication Publication Date Title
JP2016074740A5 (en)
JP2018520189A5 (en)
JP2020023518A5 (en)
WO2018060732A3 (en) Compositions and methods for treating seizure disorders
NZ598534A (en) Dosage regimen of an s1p receptor modulator
JP2017506624A5 (en)
RU2015134581A (en) NITROXIL DONORS WITH IMPROVED THERAPEUTIC INDEX
RU2013154699A (en) SCYLLO-INOSITOL FOR APPLICATION IN TREATMENT OF BEHAVIORAL AND PSYCHIC DISORDERS
JP2018526460A5 (en)
JP2017501154A5 (en)
RU2015122256A (en) Compositions containing vortioxetine and donepezil
RU2013123646A (en) COMBINED COMPOSITION
JP2017510607A5 (en)
JP2016517421A5 (en)
JP2019507786A5 (en)
FI3493812T3 (en) Combinations of imetelstat and venetoclax for the treatment of acute myeloid leukaemia
JP2016505050A5 (en)
RU2008134143A (en) PHARMACEUTICAL COMPOSITION OF CITYCOLINE, CHOLIN ALPHOSCERATE AND L-CARNITINE (OR ACETYL-L-CARNITINE) FOR THE TREATMENT AND PREVENTION OF DISEASES OF THE CENTRAL NERVOUS SYSTEM AND METHOD
JP2017061488A5 (en)
JPWO2020221821A5 (en)
WO2022026622A3 (en) Treatment of viral diseases
MX2021008986A (en) Methods of treating a patient having parkinson's disease.
JP2019535830A5 (en)
CA2469702A1 (en) Darifenacin for use in the treatment of urgency induced by overactive bladder
WO2020190900A8 (en) Abiraterone-cyclic oligomer pharmaceutical formulations and methods of formation and administration thereof